Tuesday, February 22, 2011

Statins are not associated with a decrease in all cause mortality in a high-risk primary prevention setting


  • Bernhard M Kaess1

  • Ramachandran S Vasan2

  • 1Framingham Heart Study and Klinik und Poliklinik für Innere Medizin II, University of Regensburg, Regensburg, Germany
    1. 2Framingham Heart Study and Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, Massachusetts, USA
    1. Correspondence toBernhard M Kaess
      73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702–5803, USA; kaess@bu.edu
    Commentary on:
     

    Context

    Low-density lipoprotein (LDL) cholesterol (LDL-C) is a risk factor for cardiovascular disease (CVD). Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) lower LDL-C concentrations by about 30–50% and have been shown to reduce mortality in patients with prevalent CVD. However, it is not clear whether statin treatment is beneficial in a primary prevention setting, that is in people without prevalent CVD who are at relatively lower risk. The recent results of the JUPITER trial1 have fuelled an intense debate whether statins should be given for primary prevention of CVD./.../

    No comments:

    Post a Comment